| Pipeline | Target Indication | Discovery | Preclinical | Ph1 | Ph2 | Ph3 | NDA |
|---|---|---|---|---|---|---|---|
| YPN-005 | Oncology | checked | checked | none | none | none | none |
| YPN-006 | Oncology | checked | checked | none | none | none | none |
| NF-1 | Neurology | unchecked | none | none | none | none | none |
YPN-005, an oral CDK7 inhibitor, shows a significant antitumor activity in Myc amplified solid tumors and MCL-1 overexpressed blood cancers
American Association for Cancer Research (AACR) Annual Meeting 2020 Abstract Number: 3617
YPN005, an oral CDK7 inhibitor, exhibits a significant antitumor activity in Myc-driven cancers
American Association for Cancer Research (AACR) Annual Meeting 2019
Session MS.ET06.02 - Preclinical Drug Development: Experimental and Molecular Therapeutics
Abstract Number: 2687
